20 September 2023
Sidley Represents ReCode Therapeutics in Extension to Its Series B Financing
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| James Lu Lead | Sidley | Not stated | Emerging Companies and Venture Capital | Not stated |
| Feifei Bian Lead | Sidley | Not stated | M&A and Private Equity | Not stated |
| Daniel E. Gessner | Sidley | Not stated | M&A and Private Equity | Not stated |
| Peiyu Yu | Sidley | Not stated | M&A and Private Equity | Not stated |
| Cyril Cutinha | Sidley | Not stated | M&A and Private Equity | Not stated |
| Daniel Wei | Sidley | Not stated | Emerging Companies and Venture Capital | Not stated |
| Mike Heinz | Sidley | Not stated | Capital Markets | Not stated |
| James Mendenhall | Sidley | Not stated | International Trade | Not stated |
Stated terms
- Stated value
- USD 50m (US$50 million)
- What the figure measures
- Total transaction value
- Client
- ReCode TherapeuticsIssuer
- Counterparties
- Bioluminescence Ventures (Investor)
Solasta Ventures (Investor)
OrbiMed Advisors (Investor)
AyurMaya (Investor)
Leaps by Bayer (Investor)
Vida Ventures (Investor)
MPM Capital (Investor)
EcoR1 Capital (Investor)
Sanofi Ventures (Investor)
Amgen Ventures (Investor)